Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Ottawa
$105,000.00
What is the optimal duration of anticoagulant therapy for patients with a first episode of unprovoked venous thromboembolism?
FY 2017-18
Summary
Venous thromboembolism (VTE) is a major cardiovascular disease comprising of blood clots in the leg veins and the lung vessels affecting more than 50,000 Canadians each year, and is third-leading cause of cardiovascular death. Unfortunately, more than 50% of VTE cases occur without an identifiable cause (i.e. unprovoked). In these unprovoked VTE patients, the optimal duration of treatment with blood thinning medications (i.e. anticoagulants) is a common and difficult question, due to the closely balanced risks and burdens from recurrent VTE (if treatment is stopped) and major bleeding (if treatment is continued). Deciding to stop anticoagulants after the initial 3 months, or to continue them lifelong is primarily governed by the poorly established, long-term risk of recurrence when treatment is discontinued. Furthermore, an economic evaluation of the dilemma between short versus lifelong duration of treatment for such patients has never been conducted. I will first conduct a systematic review of the literature to identify studies of patients with unprovoked VTE in whom treatment was stopped after at least 3 months of anticoagulation. Next, using meta-analytic technique, I will combine the study results to establish the long-term risk of recurrent VTE at 1, 2, 5, 10 and 20 years after stopping anticoagulation. I will then use these results to construct a decision model of unprovoked VTE patients, adopting a lifelong time horizon, and a publicly-funded healthcare system. The model will explore the crucial tradeoffs of recurrent VTE and major bleeding to determine whether considering lifelong duration of treatment, as compared to short-term therapy, is cost-effective (provides value for money). Taken together, results from this project have strong potential to provide definitive evidence needed in the decision-making process regarding the optimal duration of anticoagulation for unprovoked VTE, and thus inform policy and define clinical practice.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
387252
Name
Khan Faizan
Region
Ontario
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Doctoral Research Awards - B
Projecttitle
What is the optimal duration of anticoagulant therapy for patients with a first episode of unprovoked venous thromboembolism?
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Anticoagulant Therapy; Cost-Effectiveness Analysis; Pharmacoeconomics; Pharmacoepidemiology; Systematic Review And Meta-Analysis; Venous Thrombosis
Abstract
Venous thromboembolism (VTE) is a major cardiovascular disease comprising of blood clots in the leg veins and the lung vessels affecting more than 50,000 Canadians each year, and is third-leading cause of cardiovascular death. Unfortunately, more than 50% of VTE cases occur without an identifiable cause (i.e. unprovoked). In these unprovoked VTE patients, the optimal duration of treatment with blood thinning medications (i.e. anticoagulants) is a common and difficult question, due to the closely balanced risks and burdens from recurrent VTE (if treatment is stopped) and major bleeding (if treatment is continued). Deciding to stop anticoagulants after the initial 3 months, or to continue them lifelong is primarily governed by the poorly established, long-term risk of recurrence when treatment is discontinued. Furthermore, an economic evaluation of the dilemma between short versus lifelong duration of treatment for such patients has never been conducted. I will first conduct a systematic review of the literature to identify studies of patients with unprovoked VTE in whom treatment was stopped after at least 3 months of anticoagulation. Next, using meta-analytic technique, I will combine the study results to establish the long-term risk of recurrent VTE at 1, 2, 5, 10 and 20 years after stopping anticoagulation. I will then use these results to construct a decision model of unprovoked VTE patients, adopting a lifelong time horizon, and a publicly-funded healthcare system. The model will explore the crucial tradeoffs of recurrent VTE and major bleeding to determine whether considering lifelong duration of treatment, as compared to short-term therapy, is cost-effective (provides value for money). Taken together, results from this project have strong potential to provide definitive evidence needed in the decision-making process regarding the optimal duration of anticoagulation for unprovoked VTE, and thus inform policy and define clinical practice.
Competitiondate
201710
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Khan, Faizan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~